{"doi":"10.1016/j.intf.2025.100312","title":"Real-world efficacy of long-term teduglutide use in pediatric patients with short bowel syndrome","abstract":"Background: In patients with short bowel syndrome (SBS), teduglutide reduces dependency on parenteral support (PS) by promoting intestinal growth and absorption. We aim to describe long-term outcomes using teduglutide in a large pediatric intestinal rehabilitation and transplant center. Material and Methods: We performed a single-center, retrospective analysis of teduglutide use in patients with SBS ages 1-23 years. Sex, age, intestinal length, BMI, PS regimens, and isolated small bowel (ISB) transplant status are described. Subgroup analysis comparing younger and older patient cohorts was performed. Primary end point was a reduction in PS volume of ≥ 20 %. Results: 27 patients (10 female; mean age 8.9 years) received subcutaneous teduglutide (0.05 mg/kg/d) once daily for mean 120.8 weeks. Mean bowel length was 56.9 (SD=52.1) cm. 5 were listed for ISB transplant, 2 were \"inactive,\" and 20 were not listed. 2 patients were post-enterectomy. A decrease in PS volume of ≥ 20 % was experienced by 67 % of patients, with 30 % reaching enteral autonomy at mean 71.57 (SD=56.37) weeks (Fig. 1). Significant decreases in PS volume, hours and days, nonprotein calories, parenteral nutrition dependency index (PNDI), and lipid dose were observed (Table 2). Of patients listed at baseline, 2 remained listed, 2 were removed, and 1 was reclassified as \"inactive.\" 1 was newly listed and 2 \"inactive\" patients were removed. 19 remained unlisted.The most frequent adverse event was pyrexia. 10 patients permanently discontinued treatment at mean 62.59 (SD=55.55) weeks, 4 due to related AEs. Conclusion: Pediatric SBS patients experienced significant decreases in PS dependency, providing real-world evidence of teduglutide efficacy.","journal":"Intestinal failure.","year":2025,"id":578898,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7263,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":286076,"name":"George Mazariegos","orcid":"0000-0002-2624-8632","position":1,"is_corresponding":false},{"id":1488751,"name":"Elizabeth King","orcid":"0000-0001-7360-7004","position":2,"is_corresponding":false},{"id":1409787,"name":"Pamela Holzer","orcid":null,"position":3,"is_corresponding":false},{"id":953163,"name":"Jeffrey A. Rudolph","orcid":"0000-0002-1763-7927","position":4,"is_corresponding":false},{"id":85989,"name":"Vikram Raghu","orcid":"0000-0002-6555-9732","position":5,"is_corresponding":false},{"id":1477873,"name":"Claire Josey","orcid":"0000-0001-8247-1997","position":0,"is_corresponding":true}],"reference_count":11,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:58:24.957414Z","pmid":"41550602","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}